Registry-listed formulations

lucinactant · mesh:C502722

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • Lucinactant 175 mg/kgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Lucinactant 90 mg/kgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Lucinactant for InhalationRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
66.7%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
167%(5 trials)
Terminated
2(40%)

Phase Distribution

Phase 2
4
80%
Phase 3
1
20%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (80.0%)
Phase 31 (20.0%)

Trials by Status

completed360%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)

NCT04389671
completedphase_2

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

NCT02074059
terminatedphase_2

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

NCT00215540
terminatedphase_3

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

NCT00004500
completedphase_2

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

NCT00578734

Clinical Trials (5)

Showing 5 of 5 trials
NCT04389671Phase 2

The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)

Completed
NCT02074059Phase 2

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

Completed
NCT00215540Phase 2

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Terminated
NCT00004500Phase 3

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

Terminated
NCT00578734Phase 2

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

Completed

All 5 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
5

Names & Codes

Trade Names

SurfaxinOaerosurf